Shopping Cart 0
Cart Subtotal
USD 0

Agios Pharmaceuticals Inc (AGIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company's products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia (AML); and TIBSOVO (ivosidenib), a prescription medicine used to treat adults with AML. Its pipeline products include AG-881, a pan-IDH mutant inhibitor intended for the treatment of hematologic malignancies and solid tumors; AG-270, an inhibitor of methionine adenosyltransferase 2a; and Mitapivat, a potent activator intended for the treatment of patients with pyruvate kinase deficiency. Agios is headquartered in Cambridge, Massachusetts, the US.

Agios Pharmaceuticals Inc (AGIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Agios Pharma Enters into Co-Development Agreement with Celgene 12

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13

Licensing Agreements 14

CStone Pharma Enters into Licensing Agreement with Agios Pharma 14

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15

Agios Pharma Exercises Option For Licensing Agreement With Celgene 16

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18

Equity Offering 19

Agios Pharma Raises USD546 Million in Public Offering of Shares 19

Agios Pharma Completes Underwriter's Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21

Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23

Agios Pharma Raises USD253 Million in Public Offering of Shares 25

Agios Pharma Raises USD88 Million in Public Offering Of Shares 27

Agios Pharmaceuticals Prices Offering Of Common Stock 28

Agios Pharma Completes IPO Of Shares For USD 122 Million 29

Agios Pharmaceuticals Inc-Key Competitors 30

Agios Pharmaceuticals Inc-Key Employees 31

Agios Pharmaceuticals Inc-Locations And Subsidiaries 32

Head Office 32

Recent Developments 33

Financial Announcements 33

Aug 02, 2018: Agios Reports Second Quarter 2018 Financial Results 33

May 04, 2018: Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day 35

Feb 14, 2018: Agios Reports Fourth Quarter and Full Year 2017 Financial Results 37

Nov 01, 2017: Agios Reports Third Quarter 2017 Financial Results 39

Aug 08, 2017: Agios Reports Second Quarter 2017 Financial Results 41

May 04, 2017: Agios Reports First Quarter 2017 Financial Results 44

Feb 16, 2017: Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones 46

Corporate Communications 48

Sep 04, 2018: Agios Announces Chief Executive Officer Succession Plan 48

Dec 05, 2017: Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors 49

May 31, 2017: Agios Appoints David Scadden, M.D., to the Board of Directors 50

Jan 03, 2017: Agios Appoints Ian Clark to Board of Directors 51

Government and Public Interest 52

Mar 21, 2018: Leukemia Patient's Legacy Helps Drive Innovative Cancer Clinical Trial 52

Product News 54

12/10/2017: Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency 54

11/01/2017: Agios to Present New Data from PKR Program at the 2017 ASH Annual Meeting 56

07/23/2018: TIBSOVO (ivosidenib), an IDH1 inhibitor approved for treatment of relapsed/refractory acute myeloid leukemia with an IDH1 mutation, available for order at Biologics 57

07/20/2018: Agios' Tibsovo gains FDA approval as targeted AML treatment 58

Product Approvals 59

Feb 15, 2018: FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation 59

Dec 26, 2017: Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation 60

Clinical Trials 61

Jul 06, 2018: Northwestern University Provides Clinical Update on ivosidenib 61

Jun 18, 2018: Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused 62

Jun 04, 2018: New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients 63

Jun 02, 2018: Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions 65

Jun 02, 2018: Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent 66

Jun 01, 2018: Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors 68

May 16, 2018: Agios to Present Clinical Data on Cancer Drug Candidate AG-881 at ASCO 70

May 16, 2018: Agios to Present Clinical Data on Ivosidenib at ASCO 71

Dec 11, 2017: Data from Phase 1 Studies of Ivosidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation 73

Dec 11, 2017: New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML 75

Nov 17, 2017: Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma 77

Nov 01, 2017: Agios to Present New Data on Ivosidenib at the 2017 ASH Annual Meeting 79

Jun 24, 2017: Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency 80

Jun 03, 2017: Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma 81

May 18, 2017: Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA 83

May 17, 2017: Agios to Present New Data From Ivosidenib Phase 1 Cholangiocarcinoma Study at ASCO 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Agios Pharma Enters into Co-Development Agreement with Celgene 12

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13

CStone Pharma Enters into Licensing Agreement with Agios Pharma 14

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15

Agios Pharma Exercises Option For Licensing Agreement With Celgene 16

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18

Agios Pharma Raises USD546 Million in Public Offering of Shares 19

Agios Pharma Completes Underwriter's Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21

Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23

Agios Pharma Raises USD253 Million in Public Offering of Shares 25

Agios Pharma Raises USD88 Million in Public Offering Of Shares 27

Agios Pharmaceuticals Prices Offering Of Common Stock 28

Agios Pharma Completes IPO Of Shares For USD 122 Million 29

Agios Pharmaceuticals Inc, Key Competitors 30

Agios Pharmaceuticals Inc, Key Employees 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Agios Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Agios Pharmaceuticals Inc (Agios) is a biopharmaceutical company that focuses on the discovery and development of investigational medicines for the treatment of cancer and rare genetic metabolic disorders. The company's products include IDHIFA, an oral targeted inhibitor of the mutated IDH2 enzyme used for the treatment of patients with R/R acute myeloid leukemia (AML); and TIBSOVO (ivosidenib), a prescription medicine used to treat adults with AML. Its pipeline products include AG-881, a pan-IDH mutant inhibitor intended for the treatment of hematologic malignancies and solid tumors; AG-270, an inhibitor of methionine adenosyltransferase 2a; and Mitapivat, a potent activator intended for the treatment of patients with pyruvate kinase deficiency. Agios is headquartered in Cambridge, Massachusetts, the US.

Agios Pharmaceuticals Inc (AGIO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Agios Pharma Enters into Co-Development Agreement with Celgene 12

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13

Licensing Agreements 14

CStone Pharma Enters into Licensing Agreement with Agios Pharma 14

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15

Agios Pharma Exercises Option For Licensing Agreement With Celgene 16

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18

Equity Offering 19

Agios Pharma Raises USD546 Million in Public Offering of Shares 19

Agios Pharma Completes Underwriter's Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21

Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23

Agios Pharma Raises USD253 Million in Public Offering of Shares 25

Agios Pharma Raises USD88 Million in Public Offering Of Shares 27

Agios Pharmaceuticals Prices Offering Of Common Stock 28

Agios Pharma Completes IPO Of Shares For USD 122 Million 29

Agios Pharmaceuticals Inc-Key Competitors 30

Agios Pharmaceuticals Inc-Key Employees 31

Agios Pharmaceuticals Inc-Locations And Subsidiaries 32

Head Office 32

Recent Developments 33

Financial Announcements 33

Aug 02, 2018: Agios Reports Second Quarter 2018 Financial Results 33

May 04, 2018: Agios Provides Business Update on Discovery Research Strategy and Pipeline, Progress on Clinical Programs, Commercial Launch Preparations and Reports First Quarter 2018 Financial Results at Investor Day 35

Feb 14, 2018: Agios Reports Fourth Quarter and Full Year 2017 Financial Results 37

Nov 01, 2017: Agios Reports Third Quarter 2017 Financial Results 39

Aug 08, 2017: Agios Reports Second Quarter 2017 Financial Results 41

May 04, 2017: Agios Reports First Quarter 2017 Financial Results 44

Feb 16, 2017: Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones 46

Corporate Communications 48

Sep 04, 2018: Agios Announces Chief Executive Officer Succession Plan 48

Dec 05, 2017: Agios Appoints Jacqualyn Fouse, Ph.D., to the Board of Directors 49

May 31, 2017: Agios Appoints David Scadden, M.D., to the Board of Directors 50

Jan 03, 2017: Agios Appoints Ian Clark to Board of Directors 51

Government and Public Interest 52

Mar 21, 2018: Leukemia Patient's Legacy Helps Drive Innovative Cancer Clinical Trial 52

Product News 54

12/10/2017: Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency 54

11/01/2017: Agios to Present New Data from PKR Program at the 2017 ASH Annual Meeting 56

07/23/2018: TIBSOVO (ivosidenib), an IDH1 inhibitor approved for treatment of relapsed/refractory acute myeloid leukemia with an IDH1 mutation, available for order at Biologics 57

07/20/2018: Agios' Tibsovo gains FDA approval as targeted AML treatment 58

Product Approvals 59

Feb 15, 2018: FDA Accepts New Drug Application and Grants Priority Review for Ivosidenib in Relapsed or Refractory AML with an IDH1 Mutation 59

Dec 26, 2017: Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation 60

Clinical Trials 61

Jul 06, 2018: Northwestern University Provides Clinical Update on ivosidenib 61

Jun 18, 2018: Agios Announces Initiation of Global Phase 3 Trial (ACTIVATE) of AG-348 in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused 62

Jun 04, 2018: New Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidine Demonstrate Robust Responses and a Well Tolerated Safety Profile in Newly Diagnosed IDHm AML Patients 63

Jun 02, 2018: Study of acute myeloid leukemia patients shows protein inhibitor drug safe and effective with durable remissions 65

Jun 02, 2018: Updated Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial in IDH1m Relapsed or Refractory AML Continue to Show Durable Responses as a Single Agent 66

Jun 01, 2018: Agios Presents Data from Phase 1 Dose-Escalation Study of AG-881 in Patients with IDH Mutant Positive Advanced Glioma and Other Solid Tumors 68

May 16, 2018: Agios to Present Clinical Data on Cancer Drug Candidate AG-881 at ASCO 70

May 16, 2018: Agios to Present Clinical Data on Ivosidenib at ASCO 71

Dec 11, 2017: Data from Phase 1 Studies of Ivosidenib in Combination with Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation 73

Dec 11, 2017: New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML 75

Nov 17, 2017: Agios Presents Updated Phase 1 Data from Dose Expansion Cohort of Ivosidenib (AG-120) in Patients with IDH1 Mutant Positive Glioma 77

Nov 01, 2017: Agios to Present New Data on Ivosidenib at the 2017 ASH Annual Meeting 79

Jun 24, 2017: Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency 80

Jun 03, 2017: Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma 81

May 18, 2017: Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA 83

May 17, 2017: Agios to Present New Data From Ivosidenib Phase 1 Cholangiocarcinoma Study at ASCO 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Agios Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Agios Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

Agios Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Agios Pharma Enters into Co-Development Agreement with Celgene 12

Foundation Medicine Enters Into Agreement With Agios Pharma To Develop Cancer Diagnostics 13

CStone Pharma Enters into Licensing Agreement with Agios Pharma 14

Agios Pharma Enters into Licensing Agreement with Aurigene Discovery 15

Agios Pharma Exercises Option For Licensing Agreement With Celgene 16

Agios Pharma Enters Into Licensing Agreement With University of Pennsylvania 18

Agios Pharma Raises USD546 Million in Public Offering of Shares 19

Agios Pharma Completes Underwriter's Exercise of Over-Allotment of Public Offering of Shares for USD287 Million 21

Agios Pharma Raises USD172.5 Million in Public Offering of Shares 23

Agios Pharma Raises USD253 Million in Public Offering of Shares 25

Agios Pharma Raises USD88 Million in Public Offering Of Shares 27

Agios Pharmaceuticals Prices Offering Of Common Stock 28

Agios Pharma Completes IPO Of Shares For USD 122 Million 29

Agios Pharmaceuticals Inc, Key Competitors 30

Agios Pharmaceuticals Inc, Key Employees 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Agios Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.